Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c

Vivos Therapeutics (NASDAQ: VVOS) reported Q2 EPS of ($0.31), $0.06 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.15 million versus the consensus estimate of $5.57 million.

For earnings history and earnings-related data on Vivos Therapeutics (VVOS) click here.

You May Also Be Interested In

• Chewy (CHWY) Reports In-Line Q2 EPS, Offers Guidance
• Signet Jewelers (SIG) Tops Q2 EPS by 47c, Misses on Revenue; Offers FY27 Guidance
• Casey's General Stores (CASY) Tops Q1 EPS by 69c